Funding Opportunities of Note
- NIDA Avant-Garde Award Program for HIV/AIDS and Substance Use Disorder Research (DP1)
- Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2)
- Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01)
- HIV/AIDS High Priority Drug Abuse Research (R01)
- Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33)
- Implementing the HIV Service Cascade for Justice-Involved Populations (U01)
- Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33)
- Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34)
Program Announcements
- HIV Infection of the Central Nervous System (R01 Clinical Trial Not Allowed)
- Eradication of HIV-1 from Central Nervous system Reservoirs (R01 Clinical Trial Not Allowed)
- HIV-1 infection of the Central Nervous System (R01)
- Imaging the Persistent HIV Reservoir (R01)
- Multidisciplinary Studies of HIV/AIDS and Aging (R21 Clinical Trial Optional)
- AIDS-Science Track Award for Research Transition (R03 Clinical Trial Optional)
- Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (R34 - Clinical Trial Optional)
- Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed)
- Planning Grant for Fogarty HIV Research Training Program for Low- and Middle-Income Country Institutions (D71 Clinical Trial Not Allowed)
- Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed)
- Infrastructure Development Training Programs for Critical HIV Research at Low-and Middle-Income Country Institutions (G11 Clinical Trials Not Allowed)
- Reducing Stigma to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle-Income Countries (R21 Clinical Trial Optional)
- Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)
- Centers for AIDS Research (P30 Clinical Trial Not Allowed)
- Developmental Centers for AIDS Research (P30 Clinical Trial Not Allowed)
- Innovations in Mechanisms and Interventions to Address Mental Health in HIV Prevention and Care Continuum (R21 Clinical Trial Optional)
- Multidisciplinary Studies of HIV/AIDS and Aging (R01 Clinical Trial Optional)
Request for Applications
- PrEP for HIV Prevention among Substance Using Populations (R01 - Clinical Trial Optional)
- Martin Delaney Collaboratories for HIV Cure Research (UM1 Clinical Trial Not Allowed)
- Martin Delaney Collaboratory for Pediatric HIV Cure Research (UM1 Clinical Trial Not Allowed)
- Advancing HIV/AIDS Research through Computational Neuroscience FOA (R01 - Clinical Trial Optional)
- Limited Competition: International Epidemiology Databases to Evaluate AIDS (IeDEA) (U01 Clinical Trial Not Allowed)
- Reducing Stigma Related to Drug Use in Human Service Settings (R21 Clinical Trial Optional)
- Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, and/or Cocaine Exposures (U01 Clinical Trial Not Allowed)
- Implementing the HIV Service Cascade for Justice-Involved Populations (U01 Clinical Trial Required)
- Exploiting in vivo or in situ imaging approaches to understand HIV-relevant processes in the context of substance use disorders (R61/R33 Clinical Trials Optional)
- Exploiting Omics Assays to Investigate Molecular Regulation of Persistent HIV in Individuals with Substance Use Disorder (R61/R33 Clinical Trial Optional)
- Advancing Exceptional Research on HIV/AIDS and Substance Abuse (R01, Clinical Trial Optional)
- Exploring the Roles of Biomolecular Condensates (BMCs) in HIV replication, latency, or pathogenesis in the context of substance use disorders (R21/R33 Clinical Trial Not Allowed)
Notices of Special Interest (NOSI)
- Notice of Special Interest (NOSI): Exploring the Roles of Biomolecular Condensates (BMCs) in Substance Use Disorder and/or HIV-related processes - R01,R03,R21,333
- Notice of Special Interest (NOSI): The HIV-HCV-Substance Use Disorder Syndemic: Therapeutic Approaches - R01
Notices
- Notice of Intent to Publish a Funding Opportunity Announcement for NIDA Avant-Garde Award Program for HIV/AIDS and Drug Use Research (DP1, Clinical Trial Optional)
- Notice of Intent to Publish a Funding Opportunity Announcement for Avenir Award Program for Research on Substance Use Disorders and HIV/AIDS (DP2 Clinical Trial Optional)
- Notice of Changes to RFA-AI-19-002 "HIV/AIDS Clinical Trials Networks Statistical and Data Management Centers (UM1 Clinical Trial Required)"
- Notice of Intent to Publish a Funding Opportunity Announcement for Implementing the HIV Service Cascade for Justice-Involved Populations
- Notice of NIDA Participation in PAR-20-036 "Getting To Zero: Understanding HIV Viral Suppression and Transmission in the United States (R01 Clinical Trial Optional)"